Clinical Trial Update: A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

View source ↗

Summary

A 48-month trial is evaluating the long-term effectiveness of Elocta in maintaining joint health for individuals with Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Elocta (efmoroctocog alfa)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Hemophilia A | Status: ACTIVE_NOT_RECRUITING